GW26-e1245 Atractylenolide II and Atractylenolide III Inhibit Platelets Activities and Thrombus Formation

Antiplatelet treatment has been proved to be an effective strategy for the prevention of cardiovascular disease (CVD). However, a major disadvantage of this strategy is the increasing risk of hemorrhages. Developing new platelet inhibitors with minimal adverse effects is important for clinical